| Name | Title | Contact Details |
|---|
Synsorb Biotech Inc. is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, which include RG3039, a small molecule drug candidate in clinical development for spinal muscular atrophy; histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other related diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yields during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products are to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
EMD Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Project Farma is a patient-focused global leader in advancing technical operations from ideation through commercialization with a proven track record of planning, building, and maintaining manufacturing facilities, capital expansions, and technical operations for complex biologics and novel modalities. We provide end-to-end services for the entire manufacturing lifecycle for pharmaceutical and biotech companies, universities, hospitals, and government agencies. Project Farma has executed 100+ facility builds, retrofits and expansions, managed 400+ large scale capital projects, industrialized 10+ commercial cell, gene, and novel therapies, and managed $6B+ in technical operations capital investments. One of our core values is giving back. Volunteering at hospitals, supporting life science related fundraisers and partnering with nonprofit organizations is an integral part of our culture. In doing so, not only do we raise awareness of many life-threatening diseases, but we also bring our team and our clients team closer to the actual patients and families that will be impacted by our work. Project Farma is a PerkinElmer company. (https://www.projectfarma.com/)
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.